Primary Category:
Treatment Protocols
Disease Category:
Chronic Lymphocytic Leukemia, Leukemia
Status:
Open
A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
NCT#03701282
Eligible for screening study DCP 001
EQ9161 Quality of Life (QOL) component has reach accrual goal. Therefore, EFFECTIVE August 5, 2020, the QOL component is closed to new accrual.
